{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-001486","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.517269+00:00","generated_at":"2026-06-08T03:14:33.410354+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunic reports Q3 2023 net loss $22.8M; positive CALLIPER interim NfL data","bullets":["Net loss of $22.8M ($0.51/sh) for Q3 2023 vs $21.2M ($0.69/sh) in Q3 2022.","Cash and investments of $59.7M as of Sep 30, 2023; expected runway into Sep 2024.","Phase 2 CALLIPER trial in progressive MS met interim biomarker endpoint: serum NfL improved vs placebo across all subtypes.","Received US patent notice of allowance for vidofludimus calcium in relapsing MS, extending protection to 2041.","CALLIPER enrollment completed (467 pts); top-line data expected April 2025; ENSURE interim futility late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-001486","json":"https://secwatch.observer/filing/0001193805-23-001486.json","markdown":"https://secwatch.observer/filing/0001193805-23-001486.md","text":"https://secwatch.observer/filing/0001193805-23-001486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001486/0001193805-23-001486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001486/e619056_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:14:33.410354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8564e81ca2f4271ea84559c1f873c426fc6cf372","claim":"IMMUNIC, INC. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a corporate update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380523001486/0001193805-23-001486-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}